Newsroom | Abionic

Media & press

Tuesday, 31 May 2022

Practical Implementation of the Pancreatic Stone Protein Sepsis Test

Tuesday, 31 May 2022

Practical Implementation of the Pancreatic Stone Protein Sepsis Test

Thursday, 21 April 2022

Abionic is featured in the ICU Management & Practice journal ! 📰
Check out their article on our unique sepsis detection solution & nanofluidic technology ! ⏱🩸🩺

Thursday, 31 March 2022

Abionic is attending the 32nd ECCMID conference in Lisbon from April 23rd to 26th!📆

Friday, 25 February 2022

Sparks needs new access to investors

Monday, 07 February 2022

Abionic at the 41st ISICEM in Brussels !

Tuesday, 30 November 2021

Abionic launches ultra-fast on site COVID-19 Saliva Test aimed at schools, hotels, airports and restaurants

Monday, 04 October 2021

Abionic Webinar - Advancing the Diagnosis of Sepsis in the Intensive Care Units.

Wednesday, 28 July 2021

New Study Finds Pancreatic Stone Protein to be an Early Marker for Risk Stratification in Patients with Acute Pancreatitis

Friday, 28 May 2021

New data confirms the clinical benefit of PSP for the diagnosis of severe infections in hospitalized adults

Tuesday, 20 April 2021

The Pancreatic Stone Protein (PSP) biomarker rises earlier than C-Reactive protein (CRP) and procalcitonin (PCT) in sepsis, a new study shows.

Thursday, 08 April 2021

Great symposium on the PSP Sepsis Biomarker - hosted by Abionic and Palex at the All-Virtual Galisepsis Congress

Monday, 30 November 2020

Abionic launches first Covid-19 severity test to triage patients quickly and accurately

Wednesday, 18 November 2020

Web Symposium hosted by Abionic - Early Identification of Sepsis

Wednesday, 20 May 2020

COVID-19 : LA SOLUTION DE LA SCALE-UP ABIONIC

Wednesday, 01 April 2020

The Battle for a Better Sepsis Test

Thursday, 19 March 2020

Septic shock is one of the major complications of Covid-19. Vaud-based start-up Abionic, specialized in the miniaturization of diagnostic tests, has developed a test that can detect sepsis in five minutes.

Wednesday, 11 March 2020

Basé au Biopôle à Lausanne, la start-up Abionic a développé un test qui permet de diagnostiquer un sepsis (choc septique) en cinq minutes à partir d’une goutte de sang. Sa détection précoce devrait permettre d’aider à prévenir ce syndrome, responsable d’environ 400 décès par an en Suisse romande.

Thursday, 16 January 2020

Les tests de diagnostic ultra-rapide d’Abionic bientôt dans les hôpitaux d'Europe et des Etats-Unis

Thursday, 09 January 2020

Abionic integrates first patients in US clinical trial for sepsis diagnosis method